Grandfather and grandson with feed in water.

OSTEOCOOL™ RF ABLATION for the treatment of painful bone tumors

latest news

SIR 2021 ABSTRACT OF THE YEAR

The OsteoCool™ Post-Market Clinical Study (OPuS One) is a multicenter study collecting real-world evidence on the efficacy and safety of OsteoCool™. Twelve-month data show outcomes in 206 patients treated with OsteoCool™, as well as pain relief and improved quality of life in as soon as three days¹.

pdf OPuS One 12-Month Clinical Study data (.pdf)

See clinical evidence

Patient Feature

Cory's Story

Cory’s breast cancer metastasized to her spine and sacrum causing unrelenting lower back pain that brought her into the ER. Not wanting to remain on opioids for her pain, Cory asked her doctor about other options. Dr. Ramsin Benyamin at Millennium Pain Center in Normal, IL offered to treat Cory’s cancer pain with OsteoCool.

Info for oncologists

Info for proceduralists

Product Overview

The OsteoCool RF ablation system is cooled radiofrequency ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumors, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.

Learn about the technology

Indications, Safety, and Warnings

INDICATIONS

Intended for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body
Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy
Ablation of benign bone tumors such as osteoid osteoma

RISKS

As a consequence of electrosurgery, damage to surrounding tissue through iatrogenic injury could occur
Pulmonary embolism

Contact us for more information

*Indicates Required Field

Please select at least one option below:*

I would like to be contacted by a Medtronic representative

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

Levy J, David E, Hopkins T, et al. Improvement in Quality of Life on Patients Treated for Painful Osseous Metastases With Radiofrequency Ablation: The Opus One Study, abstract presented at Society for Interventional Radiology Annual Scientific Meeting, March 20-26, 2021, virtual. https://www.researchgate.net/publication/351170997_Abstract_No_78_Improvement_in_quality_of_life_in_patients_treated_for_painful_osseous_metastases_with_radiofrequency_ablation_the_OPuS_One_study. Accessed November 8, 2021.

^{See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu}